A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.